INOVIO dosed first subject in phase 2 segment of INNOVATE phase 2/3 trial for INO-4800 to prevent COVID-19
On Dec. 7, 2020, Inovio Pharmaceuticals announced it had dosed its first subject in a Phase 2 clinical…
-
-
INOVIO expanded global manufacturing consortium for COVID-19 vaccine candidate with Kaneka Eurogentec
On Dec. 3, 2020, Inovio Pharmaceuticals announced the execution of an agreement with Kaneka Eurogentec an affiliate of…
-
INOVIO announced initiation of phase 2/3 clinical trial for COVID-19 DNA vaccine candidate, INO-4800
On Nov. 16, 2020, INOVIO announced that it had received clearance from the the U.S. Food & Drug…
-
Data from Corvus phase 1 study of CPI-006 continued to support its potential as treatment for COVID-19
On Oct. 5, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
-
Hydroxychloroquine showed no benefit in COVID-19 prevention
On Sept. 30, 2020, researchers from the Perelman School of Medicine at the University of Pennsylvania reported results…
-
Biotechnology | COVID-19 | FDA | Infectious Disease | NIH | Vaccine
INOVIO reported FDA partial clinical hold for planned phase 2/3 trial of COVID-19 vaccine candidate INO-4800
On Sept. 28, 2020, INOVIO announced the U.S. Food and Drug Administration (FDA) had notified the company that…
-
INOVIO added Thermo Fisher Scientific to global manufacturing consortium
On Sept. 8, 2020, INOVIO announced that Thermo Fisher Scientific, the world leader in serving science, had signed…
-
RedHill Biopharma’s Opaganib awarded COVID-19 grant by State of Pennsylvania
On Sept. 3, 2020, RedHill Biopharma announced the selection of opaganib, a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2)…
-
Biotechnology | COVID-19 | FDA
OraSure’s ORAcollect-RNA device Included in EUA granted to MiraDx for SARS-CoV-2 test
On Sept. 3, 2020, OraSure Technologies announced that its ORAcollect-ﾷRNA (OR-100) collection device was included along with other…
-
OraSure’s OMNIgene-ORAL device included in EUA granted to Clinical Reference Laboratory for self-collected SARS saliva test
On Jul. 31, 2020, OraSure Technologies announced that its OMNIgene-ORAL (OM-505) saliva collection device is included in the…
-
INOVIO’s COVID-19 DNA vaccine INO-4800 provided protection with memory immune responses In non-human primates challenged with SARS-CoV-2 virus
On Jul. 30, 2020, INOVIO announced that its COVID-19 DNA vaccine INO-4800 targeting SARS-CoV-2 was effective in protecting…
-
Corvus Pharmaceuticals initiated clinical trial of novel immunotherapy for patients with COVID-19
On Jul. 7, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
-
INOVIO received $71 million contract from U.S. Dept of Defense to scale up manufacture of CELLECTRA 3PSP smart device
On Jun. 23, 2020, INOVIO announced it had received $71 million funding from the U.S. Department of Defense…
-
Seqirus’ Received Health Canada approval of first cell-based seasonal influenza vaccine
On Dec. 11, 2019, Seqirus announced that its cell-based quadrivalent influenza vaccine (QIVc) had received approval from Health…
-
Penn Medicine researchers received $97 million grant from the NIH to study traumatic brain injuries and neurodegeneration
On Oct. 24, 2019, Penn Medicine researchers received $9.7 million grant from the NIH to study traumatic brain…
-
Penn Medicine developed gene therapy to treat Duchenne muscular dystrophy (DMD
On Oct. 7, 2019, Penn Medicine announced it had developed gene therapy to treat Duchenne muscular dystrophy (DMD)…
-
Penn Medicine received $22 million from NIH HEAL Initiative to combat the national opioid crisis
On Oct. 4, 2019, Penn Medicine announced they had received $22 Million from National Institutes of Health’s (NIH)…
-
UPenn completed exclusive R&D alliance with Novartis
On Sept. 12, 2019, UPenn completed its exclusive, 7-year research and development alliance with Novartis, that spawned the…
-
The National Cancer Institute awarded a $10.7 million grant to Abramson Cancer Center to study CAR T cells in solid tumors
On Oct. 22, 2018, the National Cancer Institute (NC) awarded a $10.7 million five year grant to Abramson…
-
Korff estate gifted $5 million to advance prostate cancer research and treatments in Nebraska
On Nov. 18, 2015, the estate of Glenn Korff gifted $5 million to the Fred & Pamela Buffett…
-
FDA approved quadrivalent formulation of Fluzone Intradermal inactivated influenza vaccine
On Dec. 12, 2014, Sanofi Pasteur announced the U.S. Food and Drug Administration (FDA) had approved the supplemental…
-
Matrical Bioscience acquired by Brooks Automation for $10 million
On Jul. 23, 2013, Matrical Bioscience announced it has had been acquired by Chelmsford, Massachusetts-based Brooks Automation for…
-
The Center for Personalized Diagnostics (CPD) was established at UPenn
In Feb. 2013, the Center for Personalized Diagnostics (CPD) was established at UPenn for researching genomic and therapeutic…
-
The Basser Center for BRCA was established at Penn Medicine’s Abramson Cancer Center
In 2012, the Basser Center for BRCA was established at Penn Medicine’s Abramson Cancer Center to establish a…
-
CDC published updated recommendation for meningococcal vaccination of at-risk children age 2-10 years in MMWR
On Oct. 17, 2007, the Food and Drug Administration (FDA) approved quadrivalent meningococcal conjugate vaccine (MCV4) (Menactra®, Sanofi…
-
ACIP voted to withdraw their recommendation for rotavirus vaccine
On Oct. 22, 1999, the Advisory Committee on Immunization Practices (ACIP), after a review of scientific data from…
-
Wyeth Lederle Vaccines voluntarily withdrew Rotashield from the market
On Oct. 15, 1999, Wyeth-Lederle Vaccines announced that it was withdrawing the Rotashield vaccine from the market and…
-
FDA approved a 2-dose schedule of hepatitis B vaccination for adolescents
On Aug. 29, 1999, Merck, West Point, Pennsylvania) received approval from the FDA of a supplement to Merck’s…
-
Rotavirus vaccine, live, oral, tetravalent was licensed
On Aug. 31, 1998, Rotashield (Wyeth Laboratories, Marietta, Pennsylvania) was licensed by the U.S. Food and Drug Administration…
-
A combined Haemophilus influenzae type b conjugate and hepatitis B vaccine was licensed
On Oct. 2, 1996, the Food and Drug Administration (FDA) licensed a combined Hib conjugate and hepatitis B…
